Biotech Archives - Page 81 of 795

2 minute read

Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars

April 4, 12:53 PM

FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens treatment options. Sales slightly below consensus, but pro forma basis sees growth.

ANGO

2 minute read

CureVac, GS Partner Release Data On Influenza Vaccine Study

By Vandana Singh

April 4, 12:18 PM

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A strains prompt further optimization for influenza B strains.

BNTX

2 minute read

Smith+Nephew’s PICO Single Use Negative Pressure Wound Therapy System Provides Better Clinical Outcomes Versus Standard Of Care According To Uk National Institute For Health And Care Excellence

By Benzinga Newsdesk

April 4, 11:22 AM

Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO

SNN

3 minute read

iECURE Announces FDA Clearance Of IND Application For ECUR-506 To Initiate OTC-HOPE Trial For Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency In The U.S.; NOTE: iECURE Has Licensed The ARCUS Nuclease For ECUR-506 From Precision BioSci…

By Benzinga Newsdesk

April 4, 11:02 AM

Clinical trial sites in the United States, United Kingdom, and Australia will evaluate ECUR-506, an investigational gene editing-based therapy, in newborn males with neonatal onset Ornithine Transcarbamylase (OTC)

DTIL

2 minute read

Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data

By Vandana Singh

April 4, 10:38 AM

eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a potential candidate for ER+ breast cancer trials.

EFTR

2 minute read

After Brain Cancer Data, Candel Therapeutics’ Shares Good News From Pancreatic Cancer Study

By Vandana Singh

April 4, 10:24 AM

Candel Therapeutics updates phase 2 trial results for CAN-2409 and valacyclovir in pancreatic cancer treatment, revealing prolonged survival rates up to 28.8 months versus standard therapy's 12.5 months.

CADL

2 minute read

Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead

By Surbhi Jain

April 4, 9:34 AM

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.

ABUS

2 minute read

FibroBiologics Presents Data From Dermal Fibroblast Spheroid-Based Treatment Of Chronic Wounds In A Diabetes Mouse Model At Advanced Wound Care Summit USA

By Benzinga Newsdesk

April 4, 9:32 AM

FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using

FBLG

2 minute read

In Heart Burn Drug Zantac’s Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster

By Vandana Singh

April 4, 9:16 AM

Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.

GSK

2 minute read

FDA
News

Simulations Plus Announces U.S. FDA Renews DILIsym Software Licenses For 7th Year

By Benzinga Newsdesk

April 4, 8:35 AM

Predicting DILI risk supports informed decision-making regarding drug evaluations and approvalsSimulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation solutions for the pharmaceutical,

SLP